Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion

Journal of Virology

Volumn 74, Issue 23, 2000, Pages 11329-11338

  Ignatius, R ^a   Marovich, M ^a   Mehlhop, E ^a   Villamide, L ^a   Mahnke, K ^a   Cox, W I ^a   Isdell, F ^a   Frankel, S S ^a   Mascola, J R ^a   Steinman, R M ^a   Pope, M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3 INHIBITOR; CASPASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANARYPOX VIRUS; CELL CULTURE; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; MACACA; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ANIMALS; APOPTOSIS; AVIPOXVIRUS; DENDRITIC CELLS; HUMANS; MACACA MULATTA; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034468079     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.23.11329-11338.2000     Document Type: Article

References (65)

1. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques
2. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
3. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
4. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys
5. Dendritic cells and the control of immunity
6. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group
7. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways
8. Antigen transfer to cultured human dendritic cells using recombinant avipoxvirus vectors
9. + T cells
10. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
11. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment
12. Protection against apoptosis by the vaccinia virus SPI-2 [B13R] gene product
13. + T lymphocytes
14. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes
15. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
16. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
17. A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge
18. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
19. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
20. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells
21. Natural adjuvants: Endogenous activators of dendritic cells
22. DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances TRANS-infection of T cells
23. Coexpression of NFKB/ReL and Sp1 transcription factors in HIV-1 induced, dendritic cell-T cell syncytia
24. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis
25. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
26. Dendritic cells from skin and blood of macaques both promote SIV replication with T cells from different anatomical sites
27. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells
28. Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells
29. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands
30. Virus interactions with dendritic cells
31. HIV-1 infection of dendritic cells
32. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by pox-virus-based JE vaccine candidates
33. Type I IFNs enhance the terminal differentiation of dendritic cells
34. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
35. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
36. Langerhans cells at the sites of vaccinia virus inoculation
37. Caspases: The proteases of the apoptotic pathway
38. Applications of pox virus vectors to vaccination: An update
39. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins
40. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons
41. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1
42. Dendritic cell - T cell mixtures, isolated from the skin and mucosae of macaques, support the replication of SIV
43. An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys
44. Cytokines and immunity to viral infections
45. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
46. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
47. Inhibition of dendritic cell maturation by herpes simplex virus
48. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
49. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida
50. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
51. Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression
52. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus
53. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
54. The dendritic cell system and its role in immunogenicity
55. Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection
56. The cell surface phenotype of human natural interferon-alpha producing cells as determined by flow cytometry
57. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species
58. Efficacy studies on a canarypox-rabies recombinant virus
59. Efficacy evaluation of prime-boost protocol: Canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats
60. Measles virus induces functional TRAIL production by human dendritic cells
61. Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75
62. Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1
63. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection
64. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells
65. HIV-Dendritic cell interactions promote efficient viral infection of T cells